Zymeworks revenue drops 90.57% to $4.6 million in FY26 Q2; net loss widens to $45 millionPUBT·2 days ago, 03:22 PMTBPH+6.00%ZYME+177.00%
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Rating of "Hold" from AnalystsMarket Beat·Aug 3 at 05:29 AMTBPH+6.00%
Swiss National Bank Invests $1.22 Million in Theravance Biopharma, Inc. $TBPHMarket Beat·Aug 1 at 04:12 AMTBPH+6.00%UBS+174.00%
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 | ZYME Stock NewsStockTitan·Jul 15 at 09:00 PMTBPH+6.00%ZYME+177.00%
14:43 ET$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBPH, IRDM, LCII, and PATKprnewswire·Jul 9 at 01:45 PMIRDM+335.00%LCII+283.00%
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Hold" by AnalystsMarket Beat·Jul 9 at 05:29 AMTBPH+6.00%JPM+34.00%
Major Theravance Biopharma Investor Makes Notable Stock MoveTip Ranks·Jul 8 at 09:02 PMTBPH+6.00%ZYME+177.00%
Theravance Biopharma 10% owner Eli Samaha disposes of USD 119,359 in common sharesPUBT·Jul 8 at 03:14 PMTBPH+6.00%
Theravance Biopharma 10% owner Eli Samaha sells 336,697 common shares worth $5.78 millionPUBT·Jul 1 at 06:34 PMTBPH+6.00%
